Upgrade to SI Premium - Free Trial

BMO Capital First Take on Biogen (BIIB) Earnings

April 24, 2024 7:57 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $260.00 price target on Biogen (NASDAQ: BIIB).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments

Next Articles